← Leaderboards
David H Stokoe
University Of California San Francisco
$2,605,737
Attributed
$2,605,737
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $324.2K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,605,737 · 6
By mechanism
P50$1,627,605 · 1
R01$651,394 · 1
R21$321,899 · 1
P41$4,839 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Carolyn R Bertozzi$44,381,955
- Steven D Rosen$8,910,244
- Gordon B. Mills$27,749,983
- Sharmila Majumdar$36,277,908
- Barbara Panning$7,325,371
Others in their field
Top investigators on “Phosphorylation”
- Paul S. Aisen · Cognition Therapeutics, Inc.$88,828,963
- Alan F Horwitz · University Of Virginia Charlottesville$38,916,638
- Tony R. Hunter · Salk Institute For Biological Studies$34,955,666
- Adam L Boxer · Mayo Clinic Rochester$31,930,809
- Keith A. Johnson · Banner Health$30,350,302
- Paul Greengard · Rockefeller University$28,632,392
Research focus
Phosphorylation1-Phosphatidylinositol 3-KinaseGrantPathway InteractionsFundingSignal TransductionEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErlotinibBiological ModelsCombined Modality TherapyDiagnosisCytotoxic ChemotherapyBrain NeoplasmsCohortEgfr Gene AmplificationDrug IndustryBiochemicalAntibodiesC-Erbb-1 Proto-OncogenesCharacteristicsClinical TrialsAffectEffectiveness
Grant awards (16)
Exploiting the P13 Kinase Pathway in Human Glioma Therapy$59,989
P50 · FY2012 · CA · contact PI
Exploiting the P13 Kinase Pathway in Human Glioma Therapy$300,578
P50 · FY2011 · CA · contact PI
Exploiting the P13 Kinase Pathway in Human Glioma Therapy$314,745
P50 · FY2010 · CA · contact PI
O-GLCNAC MODIFICATION OF SIGNALING EFFECTORS IN 3T3-L1 NORMAL VS INSULIN$1,766
P41 · FY2010 · RR · contact PI
Exploiting the P13 Kinase Pathway in Human Glioma Therapy$314,335
P50 · FY2009 · CA · contact PI
Exploiting the P13 Kinase Pathway in Human Glioma Therapy$324,198
P50 · FY2008 · CA · contact PI
Exploiting the P13 Kinase Pathway in Human Glioma Therapy$313,760
P50 · FY2007 · CA · contact PI
PDK-1 as an attractive cancer therapeutic$159,036
R21 · FY2006 · CA · contact PI
PDK-1 as an attractive cancer therapeutic$162,863
R21 · FY2005 · CA
PHOSPHORYLATION OF HAMARTIN AND TUBERIN, THE PRODUCTS OF THE TSC1 AND TSC2 TUMO$24
P41 · FY2005 · RR
O-GLCNAC MODIFICATION OF SIGNALING EFFECTORS IN 3T3-L1 NORMAL VS INSULIN$24
P41 · FY2005 · RR
PHOSPHORYLATION OF HAMARTIN AND TUBERIN, THE PRODUCTS OF THE TSC1 AND TSC2 TUMOR$2,995
P41 · FY2004 · RR
O-GLCNAC MODIFICATION OF SIGNALING EFFECTORS IN 3T3-L1 NORMAL VS. INSULIN$30
P41 · FY2004 · RR
PROTEIN KINASE B PATHWAY IN CELL TRANSFORMATION$223,579
R01 · FY2002 · CA
PROTEIN KINASE B PATHWAY IN CELL TRANSFORMATION$217,068
R01 · FY2001 · CA
PROTEIN KINASE B PATHWAY IN CELL TRANSFORMATION$210,747
R01 · FY2000 · CA